<DOC>
	<DOCNO>NCT02599896</DOCNO>
	<brief_summary>Background : Antibodies help body fight infection . VRC01LS antibody direct HIV virus . HIV attack immune system . In animal , VRC01LS inactivate many type HIV virus . Researchers want see people . Objectives : To see VRC01LS safe well-tolerated people . To see level VRC01LS maintain people develop immune response . Eligibility : Healthy people age 18 50 Design : Participants screen protocol number VRC 500 ( NIH 11-I-0164 ) medical history , physical exam , blood urine test . The study last 24 48 week . Visits last 2 8 hour . Participants get VRC01LS either : - A needle arm vein - A small needle place fatty tissue skin abdomen , thigh , arm . Participants assign 1 6 group . Groups 1 4 get 1 dose VRC01LS . They follow-up visit week 24 . Groups 5 6 get 1 dose VRC01LS every 12 week ( 3 dos ) . They 4 5 visit second third dose , follow-up visit week 48 . Participants 1 3 follow-up visit week receive VRC01LS . They record temperature keep diary symptom 3 day dose . They may additional unscheduled visit . At visit , participant physical exam may blood urine test .</brief_summary>
	<brief_title>Safety Pharmacokinetics Human Monoclonal Antibody , VRC-HIVMAB080-00-AB ( VRC01LS ) , With Broad HIV-1 Neutralizing Activity , Administered Intravenously Subcutaneously Healthy Adults</brief_title>
	<detailed_description>VRC 606 : A Phase 1 , Dose-Escalation Study Safety Pharmacokinetics Human Monoclonal Antibody , VRC-HIVMAB080-00-AB ( VRC01LS ) , VRC-HIVMAB060-00-AB ( VRC01 ) , Administered Intravenously Subcutaneously Healthy Adults . Study Design : This first study VRC-HIVMAB080-00-AB ( VRC01LS ) monoclonal antibody ( MAb ) healthy adult . It dose-escalation study examine safety , tolerability , dose , pharmacokinetics VRC01LS . The hypothesis VRC01LS safe administer healthy adult intravenous ( IV ) subcutaneous ( SC ) rout . The secondary hypothesis VRC01LS detectable human serum definable half-life . With protocol amendment , Group 7 Group 8 add protocol Version 2.0 evaluate VRC01 VRC01LS safety pharmacokinetics study . Product Description : VRC-HIVMAB080-00-AB ( VRC01LS ) VRC-HIVMAB060-00-AB ( VRC01 ) human MAb target CD4 bind site HIV-1 . VRC01LS modification VRC01 MAb ( show safe human study ) addition LS , 2-amino acid mutation design improve half-life antibody . VRC01LS VRC01 develop VRC/NIAID/NIH manufacture cGMP VRC Pilot Plan operate contract Vaccine Clinical Material Program operate NIAID/VRC Leidos Biomedical Research , Inc. , Frederick , MD . Vials provide 100 mg/mL . Subjects : Healthy adult , 18-50 year age . Study Plan : There 4 open-label , dose escalation group ( Groups 1-4 ) ass VRC01LS administer IV SC per subject . 2 open-label group ( Groups 5 6 ) ass VRC01LS 5 mg/kg SC 20 mg/kg IV administer every 12 week total 3 administration per subject , 2 open-label group ( Groups 7 8 ) ass VRC01 5 mg/kg SC 20 mg/kg IV administer every 4 week total 2 administration per subject . Subjects randomize Group 1 Group 2 1:1 ratio , directly enrol Groups 3-6 per dose escalation safety evaluation plan . Enrollments Group 7 Group 8 randomize 1:1 ratio . Study Duration : Subjects follow 24 week last study product administration .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>INCLUSION CRITERIA : A volunteer must meet following criterion : 1 . Able willing complete inform consent process . 2 . 18 50 year age . 3 . Based history examination , must general good health without history condition list exclusion criterion . 4 . Willing blood sample collect , store indefinitely , use research purpose . 5 . Able provide proof identity satisfaction study clinician complete enrollment process . 6 . Screening laboratory value within 84 day prior enrollment must meet following criterion : WBC 2,50012,000/mm ( 3 ) . WBC differential either within institutional normal range accompany Principal Investigator ( PI ) designee approval . Platelets = 125,000 400,000/mm ( 3 ) . Hemoglobin within institutional normal range . Creatinine le equal 1.1 x ULN . ALT le equal 1.25 x ULN . Negative HIV infection FDA approve method detection . FemaleSpecific Criteria : 7 . If woman secually active male partner history hysterectomy , tubal ligation , menopause , agree use either prescription birth control method barrier birth control method time study enrollment last study visit , monogamous partner vasectomy . 8 . Negative betaHCG ( human chorionic gonadotropin ) pregnancy test ( urine serum ) day enrollment woman presume reproductive potential . EXCLUSION CRITERIA : A volunteer exclude one follow condition apply : 1 . Previous receipt monoclonal antibody whether licensed investigational . 2 . Weight &gt; 115 kg . 3 . History severe allergic reaction generalize urticaria , angioedema anaphylaxis within 2 year prior enrollment reasonable risk recurrence . 4 . Hypertension well control . 5 . Woman breastfeed , plan become pregnant study participation . 6 . Receipt investigational study agent within 28 day prior enrollment . 7 . Any chronic clinically significant medical condition opinion investigator would jeopardize safety right volunteer . Including , limit : diabetes mellitus type I , chronic hepatitis ; OR clinically significant form : drug alcohol abuse , asthma , autoimmune disease , psychiatric disorder , heart disease , cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 9, 2017</verification_date>
	<keyword>Dose Escalation</keyword>
	<keyword>HIV Prevention</keyword>
	<keyword>Broadly HIV-1 Neutralizing Activity</keyword>
	<keyword>Open-Label</keyword>
	<keyword>Half-Life</keyword>
</DOC>